ClinicalTrials.gg
RecruitingNCT06471790MOTION-EASEUpdated Sep 10, 2026

Inertial Sensors for Obstetrical Walking Epidural Tracking

An observational study in Pregnancy Related, Epidural; Anesthesia, Headache and Labor Complication, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Hospices Civils de Lyon · Observational

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Freedom of movement and the ability to walk are crucial during the first stage of labor, potentially reducing labor duration, cesarean section risk, epidural analgesia use, and bladder catheterization. While the clinical effects of ambulation during labor remain controversial, there is a consensus on its positive impact on the birthing experience and satisfaction.

Epidural analgesia remains the gold standard for pain control during labor, with a utilization rate of 82% in France. Recent advancements in obstetric analgesia have allowed for lower doses of analgesics, often administered via patient-controlled analgesia, which maintains the potential for ambulation during labor. However, only a small number of maternity units in France offer this technique. The main barriers include organizational issues such as unsuitable facilities, lack of wireless telemetry, and potential risks such as falls and hypotension.

Significant changes in gait characteristics are observed throughout pregnancy, particularly during the third trimester, and are studied in laboratory settings using video capture and analysis. Gait during labor is influenced by pain, fetal progression, and anatomical changes in the pelvis. The presence of epidural analgesia, where local anesthetics likely affect neural transmission, may impact motor commands and sensory feedback, further altering gait characteristics. These biomechanical aspects of labor remain understudied.

Wearable inertial sensors show promise in maternal health monitoring by providing real-time data for motion and gait studies. However, their application has not been described or validated during labor, particularly in walking conditions. Continuous dynamic study of gait in these conditions could enable non-invasive, non-intrusive monitoring of analgesia effectiveness, fall risk prediction, and labor progression analysis.

The aim of this feasibility study is to validate the use of wearable inertial sensors to quantify movements and characterize gait during the first stage of labor, both with and without low-dose epidural analgesia.

02

Conditions studied

  • Pregnancy Related
  • Epidural; Anesthesia, Headache
  • Labor Complication

Keywords

  • PREGNANCY
  • LABOR
  • EPIDURAL ANALGESIA
  • WALKING EPIDURAL
  • MOVEMENTS
  • GAIT
  • INERTIAL SENSOR
03

In context

Headache

762 studies on the registry are indexed under Headache; 134 are open to participants now.

This study's planned enrollment of 70 is below the median of 139 across 168 observational studies indexed under Headache.

Browse Headache studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,866 studies on the registry; 448 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

at-term (>= 38 gestation weeks) women admitted to the maternity facility for labor and delivery and willing low dose epidural analgesia with walking option

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pregnancy >= 38 gestation weeks
  • no significant medical history ( class ASA 1)
  • receiving low-dose epidural analgesia with ambulation (in accordance with current service protocol)
  • not opposed to the study

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in this study
  • Non-French-speaking patient
  • History of osteoarticular pathology likely to change gate (severe scoliosis, spinal surgery, congenital hip deformity, pelvic fracture, ligament or knee joint pathology)
  • adults under legal protection
  • multiple pregnancy
  • need for continuous intravenous infusion with infusion stand during ambulation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Walking Epidural Analgesia for Labor

    Pregnant women in labor who benefit from walking epidural analgesia technique will be monitored using inertial wearable sensors beginning from the first stage of labor and up to delivery.

06

What researchers measure

Primary outcomes

  1. triaxial (x, y, z) velocity changes over time unit (dV/dt) = m/s2 (meter over square second)

    gait patterns derived from accelerometer data measuring acceleration in three axes (x, y, z)

    Time frame: during walking starting from the demand of the parturient to have an epidural up to delivery

07

Study locations

1 of 1 sites recruiting
  • Hôpital de la Croix Rousse
    Lyon, 69004, France
    Recruiting
    • Mikhail DZIADZKO, MD · Contact
    • Mikhail DZIADZKO, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2027, 32 months after the start.

Of 55 non-industry observational studies under Headache, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 96. This study's planned 32 months is above that.

Counting every sponsor, half of 63 studies reached it within 21 months; a quarter within 12 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2024
First posted
Jun 24, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Jul 12, 2027
CompletionEst.
Jul 12, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06471790
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Nov 11, 2024
Primary completion
Jul 12, 2027 (estimated)
Completion
Jul 12, 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Mikhail DZIADZKO, MD
Contact
mikhail.dziadzko@chu-lyon.fr
04.26.10.93.25 ext. +33
Mikhail PH DZIADZKO, MD
principal investigator · Anesthésie Réanimation Douleur

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion